PNU 157706, a novel dual type I and II 5α-reductase inhibitor

Journal of Steroid Biochemistry and Molecular Biology

Volumn 64, Issue 3-4, 1998, Pages 179-186

  Di Salle, E ^a   Giudici, D ^a   Radice, A ^a   Zaccheo, T ^a   Ornati, G ^a   Nesi, M ^b   Panzeri, A ^b   Delos S ^c   Martin, P M ^c  

^a Res/Oncol Pharmacia Upjohn V   (Italy)

^b Nerviano Medical Sciences   (Italy)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; FINASTERIDE; ISOENZYME; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; RECOMBINANT ENZYME; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; ORAL DRUG ADMINISTRATION; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; RAT; RECEPTOR BINDING;

ANIMALIA;

EID: 0031917521     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(97)00158-1     Document Type: Article

References (43)

1. Metcalf B.W., Levy M.A., Holt D.A. Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne. TIPS. 10:1989;491-495.
2. Schröder F.H. 5α-Reductase inhibitors and prostatic disease. Clin. Endocrinol. 41:1994;139-147.
3. Brooks J.R., Berman C., Primka R.L., Reynolds G.F., Rasmusson G.H. 5α-Reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat. Steroids. 47:1986;1-19.
4. Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., Andriole G.L., Geller J., Bracken B.R., Tenover J.S., Darracott Vaughan E., Pappas F., Taylor A., Binkowitz B., Ng J. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327:1992;1185-1191.
5. Metcalf B.W., Holt D.A., Levy M.A., Erb J.M., Heaslip J.I., Brandt M., Oh H.-J. Potent inhibition of human steroid 5α-reductase (EC 1.3.1.30) by 3-androstene-3-carboxylic acids. Bioorg. Chem. 17:1989;372-376.
6. Johnsonbaugh R.E., Cohen B.R., McCormack E.M., George F.W., Wilson J.D. Effect of 14 days treatment with epristeride, an uncompetitive 5α-reductase inhibitor, on serum and prostatic testosterone and dihydrotestosterone in men with benign prostatic hyperplasia. J. Urol. 149:1993;432A.
7. Andersson S., Russell D.W. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc. Natl. Acad. Sci. USA. 87:1990;3640-3644.
8. Jenkins E.P., Andersson S., Imperato-McGinley J., Wilson J., Russell D.W. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J. Clin. Invest. 89:1992;293-300.
9. Thigpen A.E., Silver R., Guileyardo J.M., Casey M.L., McConnell J.D., Russell D.W. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J. Clin. Invest. 92:1993;903-910.
10. Waldstreicher J., Fiedler V., Hordinsky M., Swinehart J.M., Thiboutot D., Unger W., Lowe N.J., Jacobson C., Stieglitz S. Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness. J. Invest. Dermatol. 102:1994;615.
11. Patel S., Einstein M., Geissler W., Wu L., Andersson S. Immunohistochemical analysis of steroid 5α-reductase type 1 in human scalp and prostate. Ann. N. Y. Acad. Sci. 784:1995;27-39.
12. Bonkhoff H., Stein U., Aumüller G., Remberger K. Differential expression of 5α-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate. 29:1996;261-267.
13. Délos S., Iehlè C., Martin P.M., Raynaud J.P. Inhibition of the activity of "basic" 5alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J. Steroid Biochem. Molec. Biol. 48:1994;347-352.
14. Smith C.M., Ballard S.A., Worman N., Buettner R., Masters J.R.W. 5α-Reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J. Clin. Endocrinol. Metab. 81:1996;1361-1366.
15. Sutkowski D.M., Audia J.E., Goode R.L., Hsiao K.C., Leibovitch I.Y., McNulty A.M., Neubauer B.L. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY 300502, a benzoquinolinone human type I 5α-reductase inhibitor. Prostate. 6 (Suppl.):1996;62-66.
16. Russel D.W., Wilson J.D. Steroid 5α-reductase: Two genes/two enzymes. Ann. Rev. Biochem. 63:1994;25-61.
17. Andersson S., Berman D.M., Jenkins E.P., Russell D.W. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature. 354:1991;159-161.
18. Harris G.S., Azzolina B., Baginsky W.F., Cimis G., Rasmusson G.H., Tolman R.L., Raetz C.R.H., Ellsworth K. Identification of selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc. Natl. Acad. Sci. USA. 89:1992;10787-10791.
19. Levy M.A., Brandt M., Sheedy K.M., Dinh J.T., Holt D.A., Garrison L.M., Bergsma D.J., Metcalf B.W. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5α-reductase isoform 2. J. Steroid Biochem. Molec. Biol. 48:1994;197-206.
20. Peters D.H., Sorkin E.M. Finasteride, a review of its potential in the treatment of benign prostatic hyperplasia. Drugs. 46:1993;177-208.
21. 5-steroid isomerase. J. Med. Chem. 37:1994;2352-2360.
22. Kojo H., Nakayama O., Hirosumi J., Chida N., Notsu Y., Okuhara M. Novel steroid 5α-reductase inhibitor FK 143: Its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes. Molec. Pharmacol. 48:1995;401-406.
23. Blagg J., Ballard S.A., Cooper K., Finn P.W., Johnson P.S., MacIntyre F., Maw G.N., Spargo P.L. The development of non-steroidal dual inhibitors of both human 5α-reductase isozymes. Bioorg. Med. Chem. Lett. 6:1996;1517-1522.
24. 1-4-azasteroids: Toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry. 34:1995;13453-13459.
25. di Salle E., Briatico G., Giudici D., Ornati G., Zaccheo T., Buzzetti F., Nesi M., Panzeri A. Novel aromatase and 5α-reductase inhibitors. J. Steroid Biochem. Molec. Biol. 49:1994;289-294.
26. Giudici D., Briatico G., Cominato C., Zaccheo T., Iehlè C., Nesi M., Panzeri A., di Salle E. FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects. J. Steroid Biochem. Molec. Biol. 58:1996;299-305.
27. Liang T., Cascieri M.A., Cheung A.H., Reynolds G.F., Rasmusson G.H. Species differences in prostatic steroid 5α-reductases of rat, dog and human. Endocrinology. 117:1985;571-579.
28. + 4-ene-oxido-reductase; EC 1.3.1.22) in a stable and active form. J. Steroid Biochem. Molec. Biol. 38:1991;73-77.
29. di Salle E., Giudici D., Briatico G., Ornati G., Panzeri A. Hormonal effects of turosteride, a 5α-reductase inhibitor, in the rat. J. Steroid Biochem. Molec. Biol. 46:1993;549-555.
30. Iehlè C., Délos S., Filhol O., Martin P.M. Baculovirus-directed expression of human prostatic steroid 5α-reductase 1 in an active form. J. Steroid Biochem. Molec. Biol. 46:1993;177-182.
31. Iehlè C., Délos S., Guirou O., Tate R., Raynaud J.P., Martin P.M. Human prostatic steroid 5α-reductase isoforms: A comparative study of selective inhibitors. J. Steroid Biochem. Molec. Biol. 54:1995;273-279.
32. Silver R.I., Wiley E.L., Davis D.L., Thigpen A.E., Russell D.W., McConnell J.D. Expression and regulation of steroid 5α-reductase 2 in prostate disease. J. Urol. 152:1994;433-437.
33. Normington K., Russell D.W. Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes. Evidence for distinct physiological functions. J. Biol. Chem. 267:1992;19548-19554.
34. Giudici D., Briatico G., Biagini L., Cominato C., Panzeri A., di Salle E. Effect of the 5α-reductase inhibitors turosteride, finasteride and epristeride on prostatic testosterone and dihydrotestosterone in the rat. J. Endocrinol. Invest. 17(3 Suppl. 1):1994;51.
35. Lamb J.C., English H., Levandoski P.L., Rhodes G.R., Johnson R.K., Isaacs J.T. Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105657. Role for testosterone in the androgenic response. Endocrinology. 130:1992;685-694.
36. Rittmaster R.S., Magor K.E., Manning A.P., Norman R.W., Lazler C.B. Differential effect of 5α-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Molec. Endocrinol. 5:1991;1023-1029.
37. di Salle E., Giudici D., Biagini L., Cominato C., Briatico G., Panzeri A. Effect of 5α-reductase inhibitors on intraprostatic androgens in the rat. J. Steroid Biochem. Molec. Biol. 53:1995;381-385.
38. 3H ]methyltrienolone (R1881) in rat prostate and human benign prostatic hypertrophy (BPH) Steroids. 28:1976;449-459.
39. Hirsch K.S., Jones C.D., Audia J.E., Andersson S., McQuaid L., Stamm N.B., Neubauer B.L., Pennington P., Tooney R.E., Russell D.W. LY 191704: A selective, nonsteroidal inhibitor of human steroid 5α-reductase type 1. Proc. Natl. Acad. Sci. USA. 90:1993;5277-5281.
40. Bakshi R.K., Patel G.F., Rasmusson G.H., Baginsky W.F., Cimis G., Ellsworth K., Chang B., Bull H., Tolman R.L., Harris G.S. 4,7β-Dimethyl-4-azacholestan-3-one (MK 386) and related 4-azasteroids as selective inhibitors of human type 1 5α-reductase. J. Med. Chem. 37:1994;3871-3874.
41. Sahoo, S. P., Bakshi, R. K., Durette, P. L., Gratale, D., Hagmann, W. K., Lanza, T. J., Patel, G. F., Rasmusson, G. H., Von Langen, D., Harris, G. S., Bull, H. G., Chang, B. C., Ellsworth, K. P., Garcia-Calco, M., Toney, J. H., Carlin, J. R., Lee Chiu, S. H., Heck, J. V. and Tolman, R. L., Discovery of 16β-(4′chlorophenoxy)-4,7β-dimethyl-4-aza-5α-androstane-3- one (L-751,788): A potent, selective and orally active inhibitor of human type 1 5α-reductase. XIVth Int. Symp. on Medicinal Chemistry. Maastricht, The Netherlands, 8-12 Sept. 1996, Abstr., p. 5.46.
42. Schwartz J.I., Van Hecken A., De Schepper P.J., De Lepeleire I., Lasseter K.C., Shamblen E.C., Winchell G.A., Constanzer M.L., Chavez C.M., Wang D.Z., Ebel D.L., Justice S.J., Gertz B.J. Effect of MK-386, a novel inhibitor of type 1 5α-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men. J. Clin. Endocrinol. Metab. 81:1996;2942-2947.
43. Hermann D.J., Davis M.S., Wilson T.H. Effects of GI 198745 (GG745), a novel 5-alpha reductase (5AR) inhibitor, on dihydrotestosterone (DHT). Clin. Pharmacol. Ther. 59:1996;192.